| Über den Wolken: Aktie von Ryanair, Volatus Aerospace und Air France-KLM im Fokus! | Über den Wolken ist die Freiheit nicht immer grenzenlos. Hohe Kerosinpreise verderben den Airlines das Geschäft und gestiegene Ticketpreise machten den Sommerurlaub 2026 deutlich teurer. Dies gilt insbesondere... ► Artikel lesen |
| BERNSTEIN RESEARCH stuft AIR FRANCE-KLM auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat die Einstufung für Air France-KLM mit einem Kursziel von 12,20 Euro auf "Market-Perform" belassen. Während der Iran-Konflikt andauere... ► Artikel lesen |
| RBC stuft AIR FRANCE-KLM auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die kanadische Bank RBC hat das Kursziel für Air France-KLM von 10 auf 12 Euro angehoben und die Einstufung auf "Sector Perform" belassen. Ruairi Cullinane erhöhte in einer... ► Artikel lesen |
| Koninklijke Vopak N.V.: Vopak reports strong first half 2026 results, increases FY 2026 outlook and announces EUR 0.72 interim dividend | The Netherlands, 30 July 2026 Vopak reports strong first half 2026 results, increases FY 2026 outlook and announces EUR 0.72 interim dividend Key highlights Improve Net profit -including exceptional... ► Artikel lesen |
| Koninklijke Vopak N.V.: Resolutions passed by Vopak's Extraordinary General Meeting | Resolutions passed by Vopak's Extraordinary General MeetingRotterdam, the Netherlands, 29 July 2026The Extraordinary General Meeting of Koninklijke Vopak N.V. (Royal Vopak) held on 29 July 2026 passed... ► Artikel lesen |
| Koninklijke Vopak N.V.: Vopak completes acquisition of majority stake in Green Energy Storage (GES) and takes final investment decision on 200 MW/ 800 MWh battery storage project in the Netherlands | Vopak completes acquisition of majority stake in Green Energy Storage (GES) and takes final investment decision on 200 MW/ 800 MWh battery storage project in the NetherlandsRotterdam / Breda, the... ► Artikel lesen |
| Pharming Group N.V.: FDA approves Pharming's Joenja as first treatment for children with APDS in the U.S. | FDA approval expands Joenja indication to include children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS) ages 4 to 11 who weigh at least 27kgNewly approved Joenja doses are... ► Artikel lesen |
| Pharming Group N.V.: Pharming Group to participate in September investor conferences | Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. ("Pharming") (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences... ► Artikel lesen |
| Pharming Group N.V.: Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older | Launch marks first commercial availability of Joenja® (leniolisib) for children aged 4 to 11 worldwide OrphanPacific, Inc. serves as Marketing Authorization holder and is responsible for supply and... ► Artikel lesen |